MIB-626 ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 18 | Spinocerebellar degeneration | 1 |
18. Spinocerebellar degeneration
Clinical trials : 71 / Drugs : 99 - (DrugBank : 30) / Drug target genes : 45 - Drug target pathways : 65
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04817111 (ClinicalTrials.gov) | April 10, 2021 | 10/3/2021 | NAD+ Precursor Supplementation in Friedreich's Ataxia | A Phase 2a Study of NAD+ Precursor Supplementation in Friedreich's Ataxia | Friedreich Ataxia | Drug: MIB-626 | Metro International Biotech, LLC | Children's Hospital of Philadelphia | Recruiting | 18 Years | 64 Years | All | 10 | Phase 2 | United States |